Objectives: The mode of action of dysgalacticin, a large (21.5 kDa), heat-labile bacteriocin that is active against the human pathogen Streptococcus pyogenes, was investigated.
Introduction
In the past few decades, numerous studies have examined the potential role of bacteriocins as therapeutic agents to help combat the development of resistance to conventional antibiotics. 1, 2 Most bacteriocins produced by Gram-positive bacteria are relatively small (,10 kDa), heat-stable peptides, although some have been categorized as large (.10 kDa), heat-labile proteins. 3 There is a large amount of scientific literature concerning the small peptide bacteriocins, 3 -5 while reports of large bacteriocins have been relatively limited. Recently, Heng et al. 6 reported the genetic and biochemical characterization of a heat-labile, large bacteriocin (21.5 kDa) named dysgalacticin produced by Streptococcus dysgalactiae subsp. equisimilis strain W2580, 7 but its mode of action remains unknown.
The dysgalacticin structural gene, dysA, was localized to a small plasmid, pW2580 (3.04 kb) and based on protein structural prediction algorithms, it was suggested that dysgalacticin comprises a two domain-like structure: a structurally undefined N-terminal region and a helix-loop-helix C-terminal portion. 6 The topology prediction for dysgalacticin reveals clusters of hydrophobic amino acid residues in the C-terminal domain forming a region capable of inserting into a cytoplasmic membrane ( Figure 1 ). Based upon the amphipathic nature and topology predictions of dysgalacticin, we hypothesize that dysgalacticin exerts its antimicrobial activity by interacting with the cytoplasmic membrane of the susceptible cells via the hydrophobic C-terminal portion of the molecule. Dysgalacticin displays a relatively narrow spectrum of activity and is active mainly against the medically important pathogen Streptococcus pyogenes in a 'non-lytic' manner. 6, 7 This nonlytic mode of action of dysgalacticin is in direct contrast to the action of other high molecular weight bacteriocins, such as lysostaphin and zoocin A, which kill susceptible cells in a lytic manner. 8, 9 In this study, the mode of action of dysgalacticin against S. pyogenes was characterized using purified recombinant dysgalacticin. Evidence is provided indicating that dysgalacticin kills target cells by: (i) inhibiting glucose uptake by putative binding to the glucose-phosphotransferase system (PTS) and/or mannose-PTS; and (ii) causing a loss of K þ ions and dissipation of the membrane potential. To our knowledge, this is the first study to characterize the mode of action of a high molecular weight, non-lytic bacteriocin.
Materials and methods
Bacterial strains and growth conditions S. pyogenes FF22 was used as a dysgalacticin-sensitive strain and was routinely cultivated at 378C in a microaerophilic atmosphere (5% CO 2 in air) on BACa [Columbia blood agar base (Becton Dickinson, NJ, USA) containing 4% (v/v) human blood and 0.1% (w/v) CaCO 3 ] or in Todd -Hewitt broth (THB; Becton Dickinson). Escherichia coli DH5a was the host for the expression of recombinant dysgalacticin and was propagated aerobically at 378C on Luria-Bertani (LB) agar. 6 When required, ampicillin was added to LB to a final concentration of 100 mg/L.
Chemicals
Antibiotics, protonophores and ionophores were purchased from Sigma (USA). All radiolabelled isotopes (D-[U-
C]serine) were purchased from Amersham (Buckinghamshire, England), with the exception of [ 3 H]tetraphenylphosphonium (TPP þ ), which was purchased from Nuclear Supplies (Boston, USA).
Expression and purification of recombinant dysgalacticin
The expression and purification of recombinant dysgalacticin was carried out as described previously. 6 The purity of recombinant protein was assessed to be in excess of 95% by SDS-PAGE analyses, which were carried out by electrophoretic separation on pre-cast 16% Tris-Tricine gels (Invitrogen, San Diego, USA) using the manufacturer's apparatus, chemicals and protocols. Protein bands were visualized with Coomassie Brilliant Blue G250 (Bio-Rad, CA, USA). Protein concentrations were determined using Bradford protein assay (Bio-Rad) with bovine serum albumin (Invitrogen) as a standard, according to the manufacturer's instructions.
Determination of MIC and cell viability
The MIC values were determined by a standard microbroth dilution method as described previously, 10 with the exception that THB was used for bacterial growth and the microtitre plates were incubated without shaking. To determine the amount of dysgalacticin required to inhibit actively growing S. pyogenes, cells were grown to the early exponential phase (OD 600 ¼ 0.1-0.2) and increasing concentrations of purified recombinant dysgalacticin were added. The inhibitory effect on bacterial growth was measured as a change in OD 600 . Cell viability was determined by plating out cells that were serially diluted in sterile saline on BACa. Viable cell numbers were determined as cfu after 24 h incubation at 378C in a microaerophilic atmosphere. The limit of detection was 100 cfu/mL.
Preparation of cell suspensions
Cell suspensions for all assays, unless otherwise stated, were prepared from S. pyogenes cultures grown to the early exponential phase (OD 600 ¼ 0.1-0.2). The cells were harvested by centrifugation (10 000 g, 10 min, 48C), washed twice and then resuspended in KP i buffer (KH 2 PO 4 /K 2 HPO 4 ) (100 mM, pH 7.0) supplemented with 5 mM MgSO 4 to a final OD 600 of 1.0 unless otherwise stated. For measurement of intracellular K þ content, NaP i buffer (NaH 2 PO 4 /Na 2 HPO 4 ) (100 mM, pH 7.0) supplemented with 5 mM MgSO 4 was used to prepare cell suspensions.
Measurement of glucose fermentation
Cell suspensions were prepared in low ionic strength KP i buffer (5 mM, pH 7.0) supplemented with 5 mM MgSO 4 to obtain a final OD 600 of 5.0. Samples were incubated at 378C for 10 min prior to addition of glucose (100 mM final concentration). Changes in the external pH of cell suspensions were measured using a pH electrode (Mettler Toledo Inlab w 413, OH, USA) over 30 min intervals. After a 10 min period, cells were treated with one of the following compounds to achieve the final concentrations described: dysgalacticin (22 mg/L), N,N 0 -dicyclohexylcarbodiimide (DCCD, 500 mM), sodium fluoride (5 mM) or iodoacetate (5 mM).
Transport assays
Cell suspensions were prepared from overnight cultures to obtain the maximum phosphoenolpyruvate (PEP) potential. 11 Aliquots of 200 mL cell suspensions were incubated at 378C for 10 min in polystyrene test tubes. Cells were energized with glucose (20 mM final concentration) at 378C for 10 min prior to treatment with test compounds for serine transport, but not for sugar uptake [glucose and 2-deoxyglucose (2DG)]. Cells were treated with one or more of the following compounds for 10 min to achieve the final concentrations described: dysgalacticin (22 mg/L), sodium fluoride (5 mM), iodoacetate (5 mM), DCCD (100 mM), nigericin (10 mM) and valinomycin (10 mM). The radiolabelled compounds were added to samples to the following concentrations: L-[U- .87 mCi/mmol) and incubation was continued at 378C for 0-30 s. The reactions were stopped by the addition of 2 mL of ice-cold LiCl solution (100 mM) and rapid filtration through nitrocellulose filters (0.45 mm, MF TM membrane filters, Millipore, MA, USA), using a vacuum manifold (Millipore) with an applied vacuum of $80 psi. Filters were washed again with 2 mL of LiCl solution (100 mM), air-dried in 4 mL scintillation vials and resuspended in 2 mL of scintillation fluid (Amersham). The amount of radioactivity taken up by the cells was determined with a 1217 RACKBETA Liquid Scintillation Counter (LKB Wallac, IL, USA). The uptake of test compounds was expressed as nmol substrate taken up per mg protein.
The protein concentrations for the whole cells of S. pyogenes were determined as described previously. 12 A cell suspension of OD 600 1.0 had a protein content of 53 mg/L.
Measurement of membrane permeability
Membrane permeability of S. pyogenes was measured using the Live/Dead w BacLight TM Bacterial Viability Kit (L13152) from Molecular Probes (Invitrogen) according to the manufacturer's instructions. Cells were energized with glucose (20 mM final concentration) for 10 min at 378C prior to treatment with test compounds. The pore-former nisin (25 mg/L final concentration) was used as a positive control and untreated cells served as negative controls. Cell suspensions (0.5 mL) were treated with dysgalacticin (22 mg/L final concentration), and positive and negative controls at 378C and 300 mL aliquots of each sample were removed at various intervals over 60 min. Cells were kept on ice during sampling. Cells were stained by addition of 100 mL of 2Â live/dead BacLight TM staining reagent to 100 mL samples in triplicate in 96-well flatbottomed microtitre plates. Samples were mixed thoroughly by pipetting and the microtitre plate was incubated in the dark at an ambient temperature for 15 min. The fluorescence emission of green (excitation at 485 nm, emission at 530 nm) to red (excitation at 485 nm, emission at 630 nm) ratio was measured with a Cary Eclipse Fluorescence Spectrophotometer (VARIAN Inc. Corporate, CA, USA). The effect of dysgalacticin on membrane integrity was calculated by taking the green to red fluorescence ratios of the untreated samples as 0% permeable and the nisin-treated samples as 100% permeable. Membrane permeability was expressed as a green to red fluorescence ratio (530/630 nm).
Measurement of intracellular K þ content
The intracellular K þ concentration of dysgalacticin-treated S. pyogenes cells was determined as described previously, 13 with the following modification. Cells were energized with glucose (20 mM final concentration) for 10 min at 378C prior to treatment with test compounds. Nisin (25 mg/L final concentration) was used as a positive control while untreated cells served as negative controls. Cells were treated with either dysgalacticin (22 mg/L final concentration) or the positive and negative controls at 378C, and 0.5 mL samples were taken in duplicate after 10 min incubation. These samples were centrifuged (13000 g, 5 min, 228C) through 0.3 mL of silicon oil (1:1 ratio, DowCorning 550 and 556, BDH Laboratory Supplies, Poole, UK). The microcentrifuge tubes were frozen at 2808C and the bottom of the tubes containing cell pellets was removed using a pair of dog nail clippers. Cell pellets were digested with 1 mL of 3 M HNO 3 , vortexed vigorously and incubated at an ambient temperature overnight. Concentrations of intracellular K þ in the cell pellets were determined by flame photometry (Cole-Palmer 2655-00 Digital Flame Analyzer, Cole-Palmer Instrument Co., IL, USA).
Measurement of the membrane potential
The membrane potential of S. pyogenes was measured as an intracellular accumulation of [ 3 H]TPP þ as described previously. 14 Cells were energized with glucose (20 mM final concentration) at 378C for 10 min prior to treatment with test compounds. Samples treated with a combination of ionophores, nigericin and valinomycin (10 mM final concentration of each compound) were used as positive controls while untreated cells served as negative controls. As an additional positive control, cells were also treated with the protonophore carbonyl cyanide-m-chlorophenylhydrazone (CCCP, 100 mM final concentration). Energized cells were treated with dysgalacticin (22 mg/L final concentration) and the controls for 10 min at 378C, and [
3 H]TPP þ were added to these samples (1.6 mM, 2.28 mCi/mmol final concentration). Incubation continued at 378C for a further 15 min, and 0.5 mL cell samples in duplicate were centrifuged (13 000 g, 5 min, 228C) through 0.3 mL of silicon oil (1:1 ratio, DowCorning 550 and 556, BDH Laboratory Supplies). Twenty microlitres of supernatant of each sample were transferred to scintillation vials to measure the extracellular [ An intracellular volume of 2.04 mL/mg protein was used to calculate the membrane potential. 15 Non-specific TPP þ binding was estimated from cells treated with nigericin and valinomycin, compounds that in combination collapse the electrochemical gradient. 16 
Measurement of intracellular ATP content
The intracellular ATP concentration of S. pyogenes was determined by the luciferin/luciferase method as described previously. 17 
Statistical analysis
Results are expressed as means+standard error of the means (SEM). Two-tailed Student's t-tests were used to determine P values.
Results

Bactericidal effect of dysgalacticin on the growing and non-growing cells of S. pyogenes
Recombinant dysgalacticin inhibited the growth of S. pyogenes and the MIC was 0.17 mg/L. When added to exponentially growing cells, a concentration of 2.72 mg/L dysgalacticin was required to arrest cell growth. A 2 log reduction in cell numbers was observed within 1 h of dysgalacticin addition (Figure 2a) . A similar degree of killing was observed in non-growing, starved cells treated with dysgalacticin (Figure 2b ). These data indicate that dysgalacticin is bactericidal for S. pyogenes regardless of the growth phase and energy state of the cells.
Inhibitory effect of dysgalacticin on glucose fermentation S. pyogenes is a homofermentative bacterium that ferments glucose to lactic acid. 18, 19 To further study the mode of action of dysgalacticin on the energy state of the target cell, the effect of dysgalacticin on non-growing, glucose-metabolizing cells was determined as a measure of fermentative activity, indicated by a change in the external pH of the cell suspensions. When fermentation was initiated by the addition of glucose, the external pH of cell suspensions decreased by 1.0 unit within 10 min (Figure 3 ). This decrease in pH was due only to glucose fermentation, because the external pH of the samples without glucose remained unchanged. Glucose fermentation was inhibited within 5 min of dysgalacticin addition, as indicated by a lack of change in the external pH (Figure 3) , suggesting a possible inhibition of glucose uptake by S. pyogenes. However, glucose fermentation can also be inhibited by blocking glycolysis, and this was demonstrated by treating cells with either sodium fluoride or iodoacetate (known inhibitors of glycolysis), 20, 21 both of which inhibited a change in the external pH of glucose-metabolizing cells ( Figure 3 ). These findings indicate that the inhibitory effect of dysgalacticin on glucose fermentation could be due to inhibition of: (i) sugar uptake and/or (ii) glycolysis.
Inhibitory effect of dysgalacticin on [ 3 H]2DG uptake
To help discriminate between these possibilities, the effect of dysgalacticin on glucose uptake by the PEP-dependent PTS was evaluated, since this is the main form of sugar transport in streptococci. 18, 21 In fermentative bacteria such as streptococci, PEP is the major energy donor for substrate accumulation by the PTS, and starved cells maintain high intracellular concentrations of PEP. 11 To ensure the cells contained high levels of endogenous PEP, cell suspensions were prepared from cultures grown overnight. Suspensions of starved cells were treated with dysgalacticin and the effect of this on [ (Figure 4a ). Since glucose is a substrate for glycolysis as well as being the substrate for PTS uptake, the experiment was repeated with the non-metabolizable glucose analogue [ PTS system, and not inhibition of glycolysis (Figure 4b) . These results indicate that dysgalacticin inhibits glucose transport by direct interference with components of the glucose-and/or mannose-PTS, since both glucose and 2DG are transported by this system in streptococci. 22 Mannose-PTS has been reported to serve as a receptor for the binding of some class II bacteriocins that exert activity on sensitive cells in a voltage-independent manner. 23 -28 In view of the voltage-independent activity of other receptorbinding bacteriocins, we decided to determine whether the inhibitory activity of dysgalacticin was dependent on the membrane potential (DC). Cells treated with a combination of nigericin and valinomycin, ionophores that collectively dissipate both components of the electrochemical gradient 16 (i.e. DC and proton gradient, DpH), showed a similar rate of [ 3 H]2DG uptake to that of untreated cells (Figure 4c) . [ 3 H]2DG uptake was inhibited only after dysgalacticin was added to those cells pre-treated with nigericin and valinomycin (Figure 4c) . These results indicate that binding of dysgalacticin to its target, proposed to be the glucose-and/or mannose-PTS, is independent of DC.
Effect of dysgalacticin on cytoplasmic membrane permeability, intracellular K þ and membrane potential
To test the hypothesis that dysgalacticin interacts with the cytoplasmic membrane of S. pyogenes and therefore affects the membrane integrity, the effect of dysgalacticin on the cytoplasmic membrane permeability was determined. A fluorescent technique involving two fluorescent dyes, SYTO w 9 (a green fluorescent nucleic acid stain that labels all bacterial cells in a population) and propidium iodide (a red fluorescent nucleic acid stain that only penetrates cells with damaged membranes), was utilized for this purpose. When SYTO w 9 and propidium iodide are used in combination, bacteria with intact cell membranes stain fluorescent green, whereas those having damaged membranes stain fluorescent red. The degree of membrane damage can then be estimated from the fluorescence ratio of green to red. The large pore-former nisin (2 -2.5 nm) was used as a positive control. 29 The MIC value of nisin against S. pyogenes cells was 0.78 mg/L, and a concentration of nisin in excess of the MIC (25 mg/L) was used in the assay. The fluorescence ratios of the nisin-treated samples were taken to represent 100% permeability in comparison with the untreated cells. S. pyogenes cell suspensions treated with dysgalacticin showed an increase in membrane permeability after 5 min of exposure (35% increase, P,0.01), which remained unchanged after 60 min (Figure 5a ). These results indicate that dysgalacticin is not a pore-former per se like nisin, but it does appear to have a destabilizing effect on the integrity of the cell membrane. It is therefore conceivable that dysgalacticin may have an effect on the permeability of small ions, and in order to evaluate this, the effect of dysgalacticin on the intracellular K þ concentration was investigated. Cells treated with either dysgalacticin or nisin displayed a significant loss of intracellular K þ (P¼0.02) after 10 min of exposure (Figure 5b ). An 87% and a 67% reduction in intracellular K þ was observed in dysgalacticin-treated cells and nisin-treated samples, respectively (Figure 5b ). These results demonstrate that dysgalacticin causes efflux of intracellular K þ . Since K þ is a component of DC, the effect of dysgalacticin on the DC of S. pyogenes was determined by measuring the accumulation of (Figure 5d ), a result that is consistent with dysgalacticin dissipating the DC. Dysgalacticin also causes a decrease in intracellular ATP content (a 30% decrease after 5 min, which decreases further to 57% after 30 min, data not shown).
Discussion
Based on the data presented in this study, we propose that dysgalacticin exerts its bactericidal activity on S. pyogenes in a two-step process ( Figure 6 ). The first step involves the binding of dysgalacticin to the glucose-and/or mannose-PTS permease resulting in the inhibition of glucose transport. The mannose-PTS has been known to serve as a binding site for some class II bacteriocins such as leucocin A, pediocin PA-1, enterocin A, mesentericin and lactococcin A. 23 -25 The constitutive expression of the mannose-PTS in streptococci 31 suggests that the proposed receptor for dysgalacticin is always present, allowing dysgalacticin to act against sensitive cells regardless of their growth stage. This provides an explanation for the inhibition of both glucose transport and metabolism by dysgalacticin, but it does not explain why this compound is bactericidal towards S. pyogenes.
Since dysgalacticin contains clusters of hydrophobic residues at its C-terminus (Figure 1) , it seems likely that dysgalacticin interacts with the cytoplasmic membrane of S. pyogenes. 26 We propose that after the binding of dysgalacticin to the glucoseand/or mannose-PTS permease, dysgalacticin disrupts membrane permeability. This leads to a loss of intracellular K þ and dissipation of the DC, which ultimately leads to cell death and explains the bactericidal properties of dysgalacticin towards growing and non-growing cells ( Figure 6 ). Other bacteriocins reported to selectively dissipate DC by causing K þ efflux are also bactericidal towards sensitive cells. 32 -34 Our proposed model of the mode of action of dysgalacticin is not unusual, since membranepermeabilizing bacteriocins such as lactococcin A and mesentericin Y105 have been reported to use mannose-PTS as a receptor. 23, 24, 27, 28 Given the widespread nature of PTS in bacteria and its absence from eukaryotic organisms, the potential of PTS-targeting bacteriocins for future development as novel antimicrobials warrants further investigation. 
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